Researchers from the First Affiliated Hospital of Nanjing Medical University found new potential targets for the treatment of myocardial infarction

The First Affiliated Hospital of Nanjing Medical University

It has been known that mice within seven days after birth can fully regenerate hearts after myocardial infarction (MI), and several previous studies have attempted to elucidate mRNA changes in this process. Researchers from the First Affiliated Hospital of Nanjing Medical University aimed to comprehensively evaluate the connections and differences between mRNA expression and protein expression in this process and how they affect heart regeneration.

In this study, a mouse model of heart regeneration was constructed, and transcriptomic and proteomic analyses were performed to evaluate mRNA expression and protein expression. Scientists systematically characterized the molecular features during heart regeneration in neonatal mice, and Ankrd1, Gpx3, and Trim72 were identified as potential targets for heart regeneration therapy.

Researchers concluded that the process of cardiac regeneration is regulated by multiple mechanisms, and the ubiquitination process regulates regeneration at the protein level. Meanwhile, Ankrd1, Gpx3, and Trim72 may be the key genes regulating heart regeneration, as well as new potential targets for the treatment of MI.

眾所周知,小鼠在出生後 7 天內可以在心肌梗塞 (MI) 後完全再生心臟,之前的幾項研究試圖闡明這一過程中 mRNA 的變化。南京醫科大學第一附屬醫院的研究人員旨在全面評估該過程中mRNA表達和蛋白質表達之間的聯繫和差異以及它們如何影響心臟再生。

本研究構建了小鼠心臟再生模型,並進行轉錄組和蛋白質組學分析以評估mRNA表達和蛋白質表達。科學家系統地描述了新生小鼠心臟再生過程中的分子特徵,並將 Ankrd1、Gpx3 和 Trim72 確定為心臟再生治療的潛在靶點。

研究人員得出結論,心臟再生過程受多種機制調節,泛素化過程在蛋白質水平上調節再生。同時,Ankrd1、Gpx3和Trim72可能是調節心臟再生的關鍵基因,也是治療心肌梗死的新潛在靶點。

 

Reference: Liu L, Yang T, Jiang Q, Sun J, Gu L, Wang S, Li Y, Chen B, Zhao D, Sun R, Wang Q, Wang H, Wang L. Integrated transcriptomic and proteomic analysis reveals potential targets for heart regeneration. Bosn J of Basic Med Sci [Internet]. 2022Aug.23 [cited 2022Aug.27];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7770

Editor: Merima Bukva, MPharm

Be the first to comment

Leave a Reply

Your email address will not be published.


*